Menu Close

SIMON Leverages Digital Experience and Network Reach to Design Cryptocurrency Educational Platform for Wealth Managers

This post was originally published on this site

GlobeNewswire

Diabetes Drugs Market Size 2021 | Is Projected to Reach USD 78261.1 Million by 2026, Exhibiting a CAGR of 6.1%

Diabetes Drugs Market Key Players Studied in this Report Are Novo Nordisk A/S, Sanofi, Merck & Co., Inc, Eli Lilly and Company, AstraZeneca, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim International GmbH, Novartis AG, Johnson & Johnson Services, Inc, Bayer AG.Pune, India, May 24, 2021 (GLOBE NEWSWIRE) — According to the report, Diabetes Drugs market size is projected to reach USD 78261.1 Million value by 2026, exhibiting a CAGR of 6.1%. The report further mentions that the market stood at USD 48753.1 million in 2018. The drugs are administered through oral, subcutaneous, and intravenous routes. It is utilized to treat diabetes Type 1 and Type 2. According to the Centers for Disease Control and Prevention in 2017, the US alone accounted for 30.3 million diabetic patients. The increasing prevalence of diabetes among the population globally is expected to propel the demand for the product during the forecast period. COVID-19 Impact- Increasing Demand for Drugs Owing to COVID-19 Crisis to Promote Growth The market witnessed a gradual rise in the demand for diabetes drugs during the COVID-19 crisis. According to a study by BeatO in 2021, COVID positive patients with pre-existing diabetes experienced blood glucose level fluctuations. This led to a high demand for advanced drugs to treat diabetes. Additionally, the consumption of diabetes management equipment such as insulin pens, pumps, injectors, and syringes experienced considerable growth during the pandemic. Request a Sample Copy of the Research Report: https://www.fortunebusinessinsights.com/enquiry/sample/diabetes-drugs-market-100570 Market Segmentation- On the basis of drug class, the market for diabetes drugs is segmented into insulin, DPP-4 inhibitors, GLP-1 receptor agonists, SGLT2 inhibitors, and others. Based on drug class, the insulin segment held a market share of about 43.7% in 2018. Based on diabetes type, the market is bifurcated into Type 1 and Type 2. Additionally, the route of administration is classified into oral, subcutaneous, and intravenous. On the basis of the distribution channel, the market is segmented into online pharmacies, hospital pharmacies, and retail pharmacies. Based on geography, the market is divided into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. Several companies are focusing on launching generic versions of insulin for patients suffering from Type 1 and Type 2 diabetes. The generic version is expected to be cost-effective and high efficacy leading to its high adoption globally. For instance, in March 2019, Eli Lilly and Company introduced a generic version of rapid-acting Humalog insulin called Lispro. The drug was launched in the USA at half the price of Humalog. Moreover, intensive research and development by various government organizations are predicted to boost the diabetes drugs market growth. This has resulted in product launches by prominent companies in the market. For instance, in 2019, Glenmark announced the launch of Remogliflozin. This is an oral antidiabetic drug in India targeted to treat type 2 Diabetes mellitus in adults. Moreover, intensive research and development by various government organizations are predicted to boost the market growth. This has resulted in product launches by prominent companies in the market. For instance, in 2019, Glenmark announced the launch of Remogliflozin. This is an oral antidiabetic drug in India targeted to treat type 2 Diabetes mellitus in adults. Click here to get the short-term and long-term impacts of COVID-19 on this Market. Please visit: https://www.fortunebusinessinsights.com/industry-reports/diabetes-drugs-market-100570 North America is expected to hold the largest diabetes drugs market share in the forecast period due to heavy investment in research and development activities by the government. The region stood at USD 23,965.5 million in 2019 and is expected to showcase exponential growth in the forthcoming years. This is due to the growing awareness of antidiabetic drugs, new product launches, and favourable reimbursement policies. Asia Pacific is anticipated to experience considerable growth with the presence of a large geriatric population. Moreover, the production bases of certain antidiabetic drug companies in the region also promote growth. Quick Buy – Diabetes Drugs Market Research Report: https://www.fortunebusinessinsights.com/checkout-page/100570 The market for diabetes drugs is fragmented by the presence of several major companies. Moreover, stringent regulatory scenarios in most of the leading economies intensify the company stability with constant updates and quality checks required to maintain standards. The growing investment in this market is expected to exponentially boost this industry and give lucrative returns. Prominent players are focused on technological innovation by investing in research and development. List of Key Players Profiled in the Market: Novo Nordisk A/SSanofi Merck & Co., Inc. Eli Lilly and Company AstraZeneca Takeda Pharmaceutical Company Limited Boehringer Ingelheim International GmbH Novartis AG Johnson & Johnson Services, Inc. Bayer AG Have Any Query? Ask Our Experts: https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/diabetes-drugs-market-100570 Global Diabetes Drugs Market Segmentation: By Drug Class: Insulin, DPP-4 InhibitorsGLP-1 Receptor AgonistsSGLT2 Inhibitors By Diabetes Type Type 1Type 2 By Route of Administration: OralSubcutaneousIntravenous By Distribution Channel: Online pharmaciesHospital PharmaciesRetail Pharmacies By Geography: North America (USA, Canada)Europe (UK, Germany, France, Italy, Spain, Scandinavia and Rest of Europe)Asia Pacific (Japan, China, India, Australia, Southeast Asia and Rest of Asia Pacific) Latin America (Brazil, Mexico, Rest of Latin America)Middle East & Africa (South Africa, GCC, and Rest of Middle East & Africa) Get your Customized Research Report: https://www.fortunebusinessinsights.com/enquiry/customization/diabetes-drugs-market-100570 Have a Look at Related Reports: Diffuse Large B-cell Lymphoma Therapeutics Market Size, Share & Industry Analysis, By Drug Type (Chemotherapy Drugs, Targeted Drugs, Others), By Distribution Channels (Hospital Pharmacies, Retail Pharmacies and Drug Stores, Others) and Regional Forecast, 2021-2028 Metformin Hydrochloride Tablets Market Size, Share & Industry Analysis, By Type (Metformin Hydrochloride – Immediate-release, Metformin Hydrochloride – Extended-release), By Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, Others) and Regional Forecast, 2021-2028 Hemorrhagic Stroke Treatment Market Size, Share & Industry Analysis, By Drug Type (Antihypertensive, Anti-Coagulants, Anti Convulsants, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) and Regional Forecast, 2021-2028 Mycosis Fungoides Treatment Market Size, Share & Industry Analysis, By Drug Type (Topical Steroids, Mechlorethamine , Interferons, Others), By Treatment (Photodynamic Therapy, Radiation Therapy, Chemotherapy, Others), By End User (Hospitals, Speciality Clinics, Others) and Regional Forecast, 2021-2028 Diabetes Drugs Market Size, Share & Industry Analysis, By Device Type (Hand Held, Wearable), By Product (Smart Glucose Meter, Continuous Glucose Monitoring Systems, Smart Insulin Pens, Smart Insulin Pumps, Others), By End User (Hospitals, Home Healthcare, Others) and Regional Forecast, 2021-2028 About Us: Fortune Business Insights™ offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in. Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data. At Fortune Business Insights™ we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges. Contact Us: Fortune Business Insights™ Pvt. Ltd. 308, Supreme Headquarters, Survey No. 36, Baner, Pune-Bangalore Highway, Pune – 411045, Maharashtra, India. Phone:US :+1 424 253 0390UK : +44 2071 939123APAC : +91 744 740 1245Email: sales@fortunebusinessinsights.comFortune Business Insights™LinkedIn | Twitter | Blogs